Certified by Founder Lodge
OrbiMed
United States - New York, NY
INVESTOR
1 Disclosed Funding Rounds $261,000,000
164 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit f
| Company | Date | Round | Raised |
|---|---|---|---|
 Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
 Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
 Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
 Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
 Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
 Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
 ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
 Star Therapeutics |
September, 05 ,2023 | Series C | $90,000,000 |
 Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
 Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Iambic Therapeutics |
October, 06 ,2023 | Series B | $100,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Adela, Inc. |
September, 26 ,2023 | Unknown | $48,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
 Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
| Rampart Bioscience |
October, 25 ,2023 | Series A | $85,000,000 |
 Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| ADARx Pharmaceuticals Inc. |
August, 10 ,2023 | Series C | $200,000,000 |
 Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Corteria Pharmaceuticals |
September, 07 ,2023 | Series A | $69,471,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Forward Therapeutics, Inc. |
November, 09 ,2023 | Series A | $50,000,000 |
 Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
 CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Epigenic Therapeutics |
August, 30 ,2023 | Series A | $32,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Treeline Biosciences |
October, 18 ,2022 | Series A | $261,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Pathalys Pharma |
February, 07 ,2023 | Unknown | $150,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Fore Biotherapeutics |
August, 25 ,2023 | Series D | $75,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| CHARM Therapeutics |
June, 09 ,2022 | Series A | $50,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
| Triveni Bio |
October, 27 ,2023 | Series A | $92,000,000 |
| Evozyne |
September, 28 ,2023 | Series B | $81,000,000 |
| Congruence Therapeutics |
March, 07 ,2023 | Series A | $65,000,000 |
| Delfi Diagnostics |
July, 18 ,2022 | Series B | $225,000,000 |
| Aer Therapeutics, Inc. |
April, 17 ,2023 | Series A | $36,000,000 |
dezerv.
FalconX
Kristal.AI
Finary
Savart
Ricursive Intelligence | $300,000,000 | (Jan 28, 2026)
Fiddler AI | $30,000,000 | (Jan 28, 2026)
Nerd Apply | $3,200,000 | (Jan 28, 2026)
Midship | $4,150,000 | (Jan 28, 2026)
Opendate | $14,000,000 | (Jan 28, 2026)
